Part VII - Duty Rationalization The measures in the areas of licensing and pricing policies would also be complemented by appropriate fiscal policy measures designed to progressively reduce import and excise duties to the minimum possible levels and to ensure that the cumulative incidence of duty on the bulk drugs is higher than that on the inputs and drug intermediates. Duty rationalization is intended to encourage cost efficient production of bulk drugs and of high quality formulations.

• Introductory • Part II - Objectives • Part III - Rational use of Drugs • Part IV - Quality Control • Part V - Pricing • Part VI - Licensing • Part VII - Duty Rationalisation • Part VIII - Co-ordination • Part IX - Review • Annexure - I • Annexure - II • Annexure - III

Part VIII - Co-Ordination Between Health and Industry Ministries With a view to achieve better integration between the Health policies and the industrial policies in the Pharmaceutical sector, an inter-ministerial Standing Committee would be constituted in the Ministry of Industry Department of Chemicals and Petrochemicals with Secretary, Ministry of Health and officials of the other Departments and agencies concerned as members. In the first instance, the Committee would oversee the implementation of the new measures and other related decisions such as revision of the National Formulary, strengthening of the institutional and statutory arrangements for enforcing quality control, dissemination of information regarding safety and efficacy of drugs to medical and paramedical personnel, centralization of drug registration, rationalization of formulations and monitoring of adverse reactions.